European Journal of Vascular & Endovascular Surgery
Volume 33, Issue 2 , Pages 192-201 , February 2007

The Rationale for Using HMG-CoA Reductase Inhibitors (‘Statins’) in Peripheral Arterial Disease

  • G. Erez
    • ,
  • E. Leitersdorf

      Affiliations

    • Corresponding Author InformationCorresponding author. E. Leitersdorf, MD, Center for Research, Prevention and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Center, Kyriat Hadassah, Ein Kerem, P.O. Box 12221, 91120 Jerusalem, Israel.

,Accepted 24 November 2006.

References 

  1. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904–910
  2. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ. 1994;309:11–15
  3. Prospective studies collaboration . Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647–1653
  4. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–2909
  5. SPARCL Investigators . High dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  6. Kent DM. Stroke – an equal opportunity for the initiation of statin therapy. N Engl J Med. 2006;355:613–615
  7. Feringa HHH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47(6):1182–1187
  8. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson WF. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961–965
  9. National Cholesterol Education Program, Third report of the expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) – final report, NIH pub. No. 02-5215, September 2002.
  10. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006;113:463–654
  11. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25:742–748
  12. DeGroot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RGA, van der Steen AFW, et al. B-mode ultrasound assessment of Pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998;31(7):1561–1567
  13. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  14. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209–215
  15. Kinikini D, Sarfati MR, Mueller MT, Kraiss LW. Meeting AHA/ACC secondary prevention goals in a vascular surgery practice: an opportunity we cannot afford to miss. J Vasc Surg. 2006;43:781–787
  16. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg. 2005;41:816–822
  17. Kroger K. Peripheral arterial procedures and postinterventional prophylaxis. J Endovasc Ther. 2006;13:32–38
  18. Nass CM, Allen JK, Jermyn RM, Fleisher LA. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. Vasc Med. 2001;6:35–41
  19. Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, et al. Effects of Colestipol-Niacin therapy on human femoral atherosclerosis. Circulation. 1991;83:438–447
  20. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower extremity peripheral arterial disease. Circulation. 2003;107:757–761
  21. Giri J, McDermott MM, Greenland P, Guralnik JM, Criqui MH, Liu K , et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol. 2006;47(5):998–1004
  22. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81(3):333–335
  23. Scandinavian Simvastatin Survival Study, Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383–1389
  24. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of Simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711–712
  25. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of Simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359–364
  26. Mohler ER, Hiatt WR, Creager MA and for the study investigators. Cholesterol reduction with Atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481–1486
  27. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39:967–975
  28. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AFL, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107:1848–1851
  29. O'Neill-Callahan K, Katsimaglis G, Tepper MR, Ryan J, Mosby C, Ioannidis JPA, et al. Statins decrease perioperative cardiac complications in patients undergoing non-cardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) Study. J Am Coll Cardiol. 2005;45:336–342
  30. Parker Ward R, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005;104:264–268
  31. Abbruzzesse TA, Havens J, Belkin M, Donaldson MC, Whittemore MD, Liao JK, et al. Statin therapy is associated with improved graft patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004;39:1178–1185
  32. Baxter BT. Abdominal aortic aneurysm regression by medical treatment: possibility or pipe dream?. J Vasc Surg. 2006;43:1068–1069
  33. Sukhija R, Aronow WS, Sandhu R, Kahar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006;97:279–280
  34. Schouten O, van Laanen JHH, Boersma E, Vidakovic R, Feringa HHH, Dunkelgrün M, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21–26
  35. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk of coronary heart disease?. Circulation. 1999;100:354–360
  36. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003;23:554–566
  37. Giannttasio C, Mangoni AA, Failla M, Stella ML, Carugo S, Bombelli M, et al. Combined effects of hypertension and hyper-cholesterolemia on radial artery function. Hypertension. 1997;29:583–586
  38. Tomochika Y, Okuda F, Tanaka N, Wasaki Y, Tokisawa I, Aoyagi S, et al. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16:955–962
  39. Smilde TJ. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolemia. Eur J Clin Invest. 2000;30:473–480
  40. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens. 2001;14:1096–1098
  41. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis. 2001;155:245–250
  42. Giannattasio C, Mangoni AA, Failla M, Carugo S, Stella ML, Stefanoni P , et al. Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Atherosclerosis. 1996;124:249–260
  43. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39:1020–1025
  44. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low density lipoprotein cholesterol. Am J Cardiol. 2005;96(Suppl):24F–33F

 One of a series of educational articles edited by Janet Powell, UK.

PII: S1078-5884(06)00678-2

doi: 10.1016/j.ejvs.2006.11.020

European Journal of Vascular & Endovascular Surgery
Volume 33, Issue 2 , Pages 192-201 , February 2007

Article Tools

* Image Usage & Resolution